Last reviewed · How we verify

Nexletol — Competitive Intelligence Brief

Nexletol (BEMPEDOIC ACID) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Adenosine Triphosphate-Citrate Lyase Inhibitor [EPC]. Area: Metabolic.

marketed Adenosine Triphosphate-Citrate Lyase Inhibitor [EPC] ATP-citrate lyase (ACL), Niemann-Pick C1-Like 1 (NPC1L1) Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Nexletol (BEMPEDOIC ACID) — Esperion Theraps Inc. NEXLIZET reduces LDL-C by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Nexletol TARGET BEMPEDOIC ACID Esperion Theraps Inc marketed Adenosine Triphosphate-Citrate Lyase Inhibitor [EPC] ATP-citrate lyase (ACL), Niemann-Pick C1-Like 1 (NPC1L1) 2020-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Adenosine Triphosphate-Citrate Lyase Inhibitor [EPC] class)

  1. Esperion Theraps Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nexletol — Competitive Intelligence Brief. https://druglandscape.com/ci/bempedoic-acid. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: